Fig. 1
From: Inadequate reporting quality of registered genome editing trials: an observational study
Flow-chart of the search and selection of eligible clinical trials using genome editing technologies. *For this observational study “human GT products” were defined according to the FDA as „all products that meet the definition of biological products and that mediate their effects by transcription or translation of transferred genetic material, or by specifically altering host (human) genetic sequences “ [3]. The term “human genome editing” is used “to refer to the processes by which the genome sequence is changed by adding, replacing, or removing DNA base pairs” [3, 8]. †Of the remaining 81 trials, 21 (25.9%) were identified only in WHO ICTRP, 47 (58.0%) also in published review(s), and 13 (16.0%) in only published review(s). Considering primary registries in the WHO registry network, 62 trials (76.5%) were registered only in ClinicalTrials.gov, 6 (7.4%) both in ClinicalTrials.gov and EU Clinical Trials Register (EU-CTR) (2 trials had equal protocol registered for 2 EU member states), 1 (1.2%) only in EU-CTR, and 12 (14.8%) trials only in Chinese Clinical Trial Registry (ChiCTR)